SFEBES2016 Oral Communications Pregnancy and Reproductive Health (6 abstracts)
Two doses of kisspeptin improve oocyte maturation and implantation rates compared to a single kisspeptin injection during IVF treatment
Ali Abbara 1 , Sophie Clarke 1 , Rumana Islam 2 , Julia Prague 1 , Alexander Comninos 1 , Shakunthala Narayanaswamy 1 , Deborah Papadopolou 1 , Rachel Roberts 1 , Alexander Nesbitt 1 , Chioma Izzi-Engbeaya 1 , Sunitha Vimalesvaran 1 , Risheka Ratnasabapathy 1 , Rehan Salim 2 , Stuart Lavery 2 , Stephen Bloom 1 , Geoffrey Trew 2 & Waljit Dhillo 1
1Imperial College London, London, UK; 2Imperial College Healthcare NHS Trust, London, UK.
Background: In vitro fertilisation is an effective therapy for infertility, but can result in the potentially life-threatening complication, Ovarian Hyper-Stimulation Syndrome (OHSS). We have previously reported that a single injection of kisspeptin results in an LH surge of ~12–14 hrs duration, sufficient to safely induce oocyte maturation, but eliminate OHSS. However, the physiological LH surge in a normal menstrual cycle has a plateaux lasting 24–28 hrs. Thus, we hypothesised that by administering a second dose of kisspeptin to women with infertility during IVF treatment, the duration of LH-exposure will more closely mimic the physiological LH-surge and hence optimise oocyte yield and pregnancy rates.
Methods: We conducted a phase2 single-blinded randomised placebo-controlled trial of 58 women at high risk of OHSS at Hammersmith IVF unit. Following a standard recombinant FSH/GnRH-antagonist IVF protocol, all patients received a subcutaneous injection of kisspeptin at 9.6 nmol/kg 36 hrs prior to egg retrieval. Patients were then randomised 1:1 to receive either a second dose of kisspeptin 10 hrs later (D; Double), or saline placebo (S; Single). IVF physicians, embryologists and participants were blinded to the randomisation. Retrieved eggs were assessed for maturation, fertilised by ICSI, with subsequent transfer of 1–2 embryos.
Outcome Measures: 1. Serum LH levels
2. Oocyte Yield (%mature eggs retrieved from follicles ≧14 mm).
3. Implantation rates
4. OHSS occurrence
Results: A double dose of kisspeptin resulted in:
1. Further rise in LH-secretion (mean change in LH at 4 hrs post-second injection (S:−12.1 iU/L, D:+4.0 iU/L; P<0.0001).
2. Optimal oocyte yield (≥60%) in more patients (S:45%, D:72%).
3. Improved implantation rate (S:25%, D:38%).
4. No moderate or severe OHSS.
Conclusion: Two doses of kisspeptin administered to women with infertility during IVF treatment induces a more physiological LH-surge, improves oocyte yield and implantation rates, without OHSS. These findings identify kisspeptin as a safe and highly effective trigger for oocyte maturation in young women suffering with infertility undergoing IVF treatment.
Volume 44
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more